<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>US FDA declines to approve Summit lung cancer drug after trial misses key survival goal — Live Feed</title><link>https://www.live-feeds.com/feed/us-fda-declines-to-approve-summit-lung-cancer-drug-after-trial-misses-key-survival-goal</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/us-fda-declines-to-approve-summit-lung-cancer-drug-after-trial-misses-key-survival-goal/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>FDA Declines to Approve Summit Lung Cancer Drug Ivonescimab</title><link>https://www.live-feeds.com/feed/us-fda-declines-to-approve-summit-lung-cancer-drug-after-trial-misses-key-survival-goal</link><guid isPermaLink="false">https://www.live-feeds.com/feed/us-fda-declines-to-approve-summit-lung-cancer-drug-after-trial-misses-key-survival-goal#u208586</guid><pubDate>Thu, 19 Nov 2026 09:41:05 +0000</pubDate><description>The US Food and Drug Administration declined to approve Summit Therapeutics&amp;#039; lung cancer drug ivonescimab after a clinical trial missed a key survival goal. The rejection derails the United States arrival of the much-hyped PD-1xVEGF class of treatments and serves as a blow to Beijing&amp;#039;s biotech sector, as the drug was invented in China by partner Akeso. Following the regulatory decision, Summit Therapeutics provided an update regarding the biologics license application while company stock plunged overnight.Why it mattersThe decision halts the introduction of a closely watched therapy </description></item>
</channel></rss>